Anaïs Lemyre
Anaïs Lemyre has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Jane Paula Messina
School of Geography and the Environment, University of Oxford, Oxford, UK
4 shared publications - Emma Claire Palmer-Cooper
School of Psychology, Centre for Innovation in Mental Health, University of Southampton, United Kingdom
3 shared publications - Benjamin W. Chrisinger
Department of Community Health, Tufts University , Medford, MA 02155
2 shared publications Andrew J. Cutler
Department of Psychiatry, Norton College of Medicine, SUNY Upstate Medical University, 750 E Adams St, Syracuse, NY, 13210, USA
1 shared publicationAntoine C. El Khoury
Johnson & Johnson Innovative Medicine, 920 US-202, Raritan, NJ, 08869, USA
1 shared publication- Carol Mao
Johnson & Johnson, Horsham, PA, United States
1 shared publication
Latest Publications
- Open Access
- 12 June 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (9) , 4079-4103
Efficacy and Safety of Lumateperone and Other Atypical Antipsychotics Approved as Adjunctive Treatment for Major Depressive Disorder in the United States: A Network Meta-Analysis
Atypical antipsychotics are common adjunctive therapies for major depressive disorder (MDD) with inadequate antidepressant (ADT) response. In 2025, lumateperone was approved in the US as adjunctive treatment for adults with MDD, and comparative evidence is lacking. This network meta-analysis compared the efficacy and safety of lumateperone with those of other approved atypical antipsychotics for MDD. Registrational randomized clinical trials as documented in US product labeling (RCTs; N = 10; aripiprazole, brexpiprazole, cariprazine, lumateperone, and quetiapine XR) were used to build a star-shaped, 11-treatment-dose node network anchored on placebo + ADT. Outcomes available for ≥ 9 RCTs were considered. Efficacy outcomes comprised change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), MADRS response and remission, and change from baseline in Clinical Global Impression-Severity (CGI-S) scale. Safety outcomes included weight change from baseline, akathisia, and somnolence. A fixed-effect Bayesian approach was applied. Pairwise treatment effects were compared; a probability of superiority > 85% (< 15%) indicated favored (unfavored) treatment. Network-wide treatment ranking was estimated using Surface Under the Cumulative Ranking (SUCRA) curves. Based on MADRS change from baseline, all atypical antipsychotics were favored versus placebo + ADT, with mean difference from placebo highest for lumateperone 42 mg/day (- 4.70). Other efficacy endpoints showed a consistent pattern, with active treatments favored over placebo + ADT across most nodes for response (10/11), remission (6/11), and CGI-S change (10/11). SUCRA ranking placed lumateperone as the treatment with the highest likelihood of being most efficacious across endpoints. Treatments differed in their safety profiles. Lumateperone was the only node with no weight gain relative to placebo and ranked first for weight-related safety outcomes. Lumateperone also ranked better than average for akathisia risk but below average for somnolence risk. Lumateperone represents an effective adjunctive therapy for adult MDD, with no weight change.
- 12 June 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (9) , 4079-4103
Open AccessEfficacy and Safety of Lumateperone and Other Atypical Antipsychotics Approved as Adjunctive Treatment for Major Depressive Disorder in the United States: A Network Meta-Analysis
Atypical antipsychotics are common adjunctive therapies for major depressive disorder (MDD) with inadequate antidepressant (ADT) response. In 2025, lumateperone was approved in the US as adjunctive treatment for adults with MDD, and comparative evidence is lacking. This network meta-analysis compared the efficacy and safety of lumateperone with those of other approved atypical antipsychotics for MDD. Registrational randomized clinical trials as documented in US product labeling (RCTs; N = 10; aripiprazole, brexpiprazole, cariprazine, lumateperone, and quetiapine XR) were used to build a star-shaped, 11-treatment-dose node network anchored on placebo + ADT. Outcomes available for ≥ 9 RCTs were considered. Efficacy outcomes comprised change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), MADRS response and remission, and change from baseline in Clinical Global Impression-Severity (CGI-S) scale. Safety outcomes included weight change from baseline, akathisia, and somnolence. A fixed-effect Bayesian approach was applied. Pairwise treatment effects were compared; a probability of superiority > 85% (< 15%) indicated favored (unfavored) treatment. Network-wide treatment ranking was estimated using Surface Under the Cumulative Ranking (SUCRA) curves. Based on MADRS change from baseline, all atypical antipsychotics were favored versus placebo + ADT, with mean difference from placebo highest for lumateperone 42 mg/day (- 4.70). Other efficacy endpoints showed a consistent pattern, with active treatments favored over placebo + ADT across most nodes for response (10/11), remission (6/11), and CGI-S change (10/11). SUCRA ranking placed lumateperone as the treatment with the highest likelihood of being most efficacious across endpoints. Treatments differed in their safety profiles. Lumateperone was the only node with no weight gain relative to placebo and ranked first for weight-related safety outcomes. Lumateperone also ranked better than average for akathisia risk but below average for somnolence risk. Lumateperone represents an effective adjunctive therapy for adult MDD, with no weight change.
- Open Access
- 23 January 2024
- Published by Wiley in British Educational Research Journal
- Vol. 50 (3) , 1281-1307
Mental wellbeing among higher education students in England during the pandemic: A longitudinal study of COVID‐19 experiences, social connectedness and greenspace use
The COVID‐19 pandemic control measures substantially impacted the life of university students in the UK. While multiple studies investigated early stages of the pandemic, focusing on risk factors for depression and anxiety, fewer studies assessed later phases of the pandemic or examined positive protective factors for mental wellbeing. Our longitudinal study investigated changes and associations between COVID‐19 experiences, lifestyle behaviours, social connectedness and mental wellbeing in the second year of the pandemic. The validated Warwick–Edinburgh Mental Wellbeing Scale was used to measure the primary outcome mental wellbeing. Self‐reported data from 161 university students (18–35‐year‐old) in England was obtained. Data collection took place across two time points with contrasting COVID‐19 epidemiological and countermeasure attributes. T1 occurred in the spring of 2021, during the tail end of the third national lockdown when indoor household mixing was prohibited and vaccination rates were low among 18–35 year olds. T2 took place 6 months later, in the autumn of 2021, when restrictions had ended and vaccination rates were high. Within‐participant changes in students showed that mental wellbeing significantly improved over 6 months, suggesting positive adjustment. Fear of COVID‐19 and engagement in COVID‐19 protective behaviours significantly decreased as pandemic restrictions eased. Physical activity levels were high and did not change over time, while greenspace visits significantly diminished. Social support remained the same and group membership significantly increased over time. Hierarchal regressions revealed that social support was the most critical contributor to mental wellbeing. We discuss lessons for mental wellbeing promotion strategies: encouraging the use of greenspace as locations for distanced social interaction and physical activity in times of lockdown constraints.
- 23 January 2024
- Published by Wiley in British Educational Research Journal
- Vol. 50 (3) , 1281-1307
Open AccessMental wellbeing among higher education students in England during the pandemic: A longitudinal study of COVID‐19 experiences, social connectedness and greenspace use
The COVID‐19 pandemic control measures substantially impacted the life of university students in the UK. While multiple studies investigated early stages of the pandemic, focusing on risk factors for depression and anxiety, fewer studies assessed later phases of the pandemic or examined positive protective factors for mental wellbeing. Our longitudinal study investigated changes and associations between COVID‐19 experiences, lifestyle behaviours, social connectedness and mental wellbeing in the second year of the pandemic. The validated Warwick–Edinburgh Mental Wellbeing Scale was used to measure the primary outcome mental wellbeing. Self‐reported data from 161 university students (18–35‐year‐old) in England was obtained. Data collection took place across two time points with contrasting COVID‐19 epidemiological and countermeasure attributes. T1 occurred in the spring of 2021, during the tail end of the third national lockdown when indoor household mixing was prohibited and vaccination rates were low among 18–35 year olds. T2 took place 6 months later, in the autumn of 2021, when restrictions had ended and vaccination rates were high. Within‐participant changes in students showed that mental wellbeing significantly improved over 6 months, suggesting positive adjustment. Fear of COVID‐19 and engagement in COVID‐19 protective behaviours significantly decreased as pandemic restrictions eased. Physical activity levels were high and did not change over time, while greenspace visits significantly diminished. Social support remained the same and group membership significantly increased over time. Hierarchal regressions revealed that social support was the most critical contributor to mental wellbeing. We discuss lessons for mental wellbeing promotion strategies: encouraging the use of greenspace as locations for distanced social interaction and physical activity in times of lockdown constraints.
- Open Access
- 28 November 2023
- Published by Taylor & Francis in Cities & Health
- Vol. 8 (2) , 155-170
Neighbourhood greenspaces and mental wellbeing among university students in England during the COVID-19 pandemic: an online survey under lockdown
- 28 November 2023
- Published by Taylor & Francis in Cities & Health
- Vol. 8 (2) , 155-170
Open AccessNeighbourhood greenspaces and mental wellbeing among university students in England during the COVID-19 pandemic: an online survey under lockdown
- Open Access
- 17 October 2023
- Published by Elsevier in Environmental Research
- Vol. 239, 117360
Greenspace use during the COVID-19 pandemic: A longitudinal population mobility study in the United Kingdom
- 17 October 2023
- Published by Elsevier in Environmental Research
- Vol. 239, 117360
Open AccessGreenspace use during the COVID-19 pandemic: A longitudinal population mobility study in the United Kingdom
- Open Access
- 4 August 2023
- Published by Elsevier in Public Health
- Vol. 222, 125-133
Wellbeing among university students during the COVID-19 pandemic: a systematic review of longitudinal studies
- 4 August 2023
- Published by Elsevier in Public Health
- Vol. 222, 125-133
Open AccessWellbeing among university students during the COVID-19 pandemic: a systematic review of longitudinal studies